Clinical Trials | April 22, 2026
Novo Nordisk’s Etavopivat delivers major Phase 3 win in sickle cell disease
By cutting pain crises & boosting haemoglobin
By cutting pain crises & boosting haemoglobin
This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease
Masitinib targets mast cells, which play a critical role in severe forms of SCD and its complications, including vaso-occlusive crises, acute chest syndrome, and pain
Inclacumab was generally well tolerated in THRIVE-131
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
Pfizer's decision is based on the totality of clinical data
This new medication eliminates the need for cold storage, making it more accessible and affordable for SCD patients across India
The National Sickle Cell Anaemia Elimination Mission was launched on 1st July 2023 at Shahdol, Madhya Pradesh
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Subscribe To Our Newsletter & Stay Updated
